Patents Examined by Richard G Hutson
-
Patent number: 11965183Abstract: The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.Type: GrantFiled: October 13, 2021Date of Patent: April 23, 2024Assignee: Oxford Nanopore Technologies PLCInventors: Andrew John Heron, Rebecca Victoria Bowen, Mark Bruce, Lakmal Jayasinghe, Joseph Hargreaves Lloyd, Szabolcs Soeroes, Elizabeth Jayne Wallace, Christopher Peter Youd
-
Patent number: 11965188Abstract: The invention relates generally to recombinant human sialidases and recombinant sialidase fusion proteins, wherein the sialidase optionally contains one or more mutations compared to wild-type human sialidase, e.g., a substitution, deletion, or addition of at least one amino acid. The invention also provides antibody conjugates including a sialidase and an antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.Type: GrantFiled: January 3, 2019Date of Patent: April 23, 2024Assignee: Palleon Pharmaceuticals Inc.Inventors: Li Peng, Lizhi Cao, Lihui Xu
-
Patent number: 11952598Abstract: Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.Type: GrantFiled: June 4, 2021Date of Patent: April 9, 2024Assignee: NUTRITION & BIOSCIENCES USA 4, INC.Inventors: Yougen Li, Mark S. Payne, Jared B. Parker, Slavko Kralj, Veli Alkan, Richard R. Bott, Robert Dicosimo, Qiong Cheng, Ellen D. Semke, Susan Marie Hennessey
-
Patent number: 11946082Abstract: The present invention features fusion polypeptides comprising an RNA binding polypeptide operationally linked to an RNA modifying enzyme (e.g., adenosine deaminase, cytidine deaminase), and methods of use therefore.Type: GrantFiled: May 13, 2022Date of Patent: April 2, 2024Assignee: Brandeis UniversityInventors: Michael Rosbash, Aoife McMahon, Weijin Xu, Hua Jin
-
Patent number: 11939606Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.Type: GrantFiled: February 23, 2022Date of Patent: March 26, 2024Assignee: Locanabio, Inc.Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
-
Patent number: 11932883Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.Type: GrantFiled: May 13, 2021Date of Patent: March 19, 2024Assignee: Locanabio, Inc.Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
-
Patent number: 11926860Abstract: Provided are a method of screening an inhibitor of caspase activity by lipopolysaccharide and a method of screening a therapeutic agent for inflammatory diseases or sepsis using the same. Accordingly, it is possible to develop a caspase-4-specific inhibitor.Type: GrantFiled: September 27, 2021Date of Patent: March 12, 2024Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hak Suk Chung, Jinsu An, Eun Gyeong Yang, So Yeon Kim
-
Patent number: 11920178Abstract: The present invention relates to the use of type III polyketide synthases of bacteria, such as actinomycete bacteria, as phloroglucinol synthases. The present invention also relates to the isolated nucleic acid molecules encoding these type III polyketide synthases, and also to the vectors and the host cells comprising such nucleic acid molecules. The present invention also relates to methods for producing phloroglucinol.Type: GrantFiled: June 29, 2018Date of Patent: March 5, 2024Assignee: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELINInventors: Vincent Lafaquiere, Odile Ramaen, Dominique Louis
-
Patent number: 11913038Abstract: Provided are nucleic acids encoding engineered polymerases comprising at least one modification in a motif A and/or at least one modification in a motif B of the polymerase and engineered polymerases encoded by the nucleic acids. Also provided are engineered DNA polymerases comprising a variant of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, the variant being at least 80% identical to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and comprising an amino acid substitution at one or more positions selected from the group consisting of L408, Y409, P410, R484, A/L485, and I486. Methods, vectors, kits, and compositions comprising the nucleic acids and compositions, methods and kits comprising the engineered polymerases are also provided.Type: GrantFiled: December 29, 2021Date of Patent: February 27, 2024Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.Inventor: Pinar Iyidogan
-
Patent number: 11913044Abstract: Some aspects of this disclosure relate to strategies, systems, methods, compositions, and kits that are useful for production (e.g., evolution) of cytidine deaminase protein variants that are characterized by increased soluble expression and/or stability relative to the wild-type cytidine deaminase protein from which they are evolved. In some embodiments, evolved cytidine deaminase variants described by the disclosure are useful for incorporation into targeted nucleic acid editing proteins, for example in fusion proteins with a Cas9 domain or variant thereof.Type: GrantFiled: June 14, 2019Date of Patent: February 27, 2024Assignees: President and Fellows of Harvard College, The Broad Institute, Inc.Inventors: David R. Liu, Tina Wang
-
Patent number: 11912991Abstract: Embodiments of the disclosure concern methods and compositions related to generation and/or use of proofreading reverse transcriptases, including those that are thermophilic or hyperthermophilic. The disclosure encompasses specific recombinant polymerases and their use. In some embodiments, the polymerases are utilized for RNA sequencing in the absence of generation of a cDNA intermediate.Type: GrantFiled: November 13, 2020Date of Patent: February 27, 2024Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Andrew Ellington, Jared Ellefson, Jimmy Gollihar
-
Patent number: 11891659Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing or nucleic acid amplification. Such properties include enhanced performance with large nucleotide analogs, increased stability, increased readlength, and improved detection of modified bases, and can also include resistance to photodamage, enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased accuracy, altered speed, increased cosolvent resistance, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.Type: GrantFiled: November 10, 2021Date of Patent: February 6, 2024Assignee: Pacific Biosciences of California, Inc.Inventors: Satwik Kamtekar, Erik Miller
-
Patent number: 11879154Abstract: The present disclosure belongs to the technical field of genetic modification of an enzyme preparation and particularly relates to a preparation method of a high-stability superoxide dismutase with a transmembrane capability. The method includes the following steps: extracting mRNA from Geobacillus stearothermophilus, synthesizing cDNA by a reverse transcription method, amplifying a large number of coding regions of the cDNA by designing a specific primer, ligating the coding regions to an E. coli expression vector, and transforming the coding regions into engineering bacteria BL21 (DE3). A point mutation technology is used to enhance stability of the superoxide dismutase and a flexible polypeptide linker GGGSGGGS (SEQ ID NO: 11) is designed, such that a soluble fusion expression of a transmembrane peptide YGRKKRRQRRR (SEQ ID NO: 10) and the superoxide dismutase is successfully realized.Type: GrantFiled: December 28, 2021Date of Patent: January 23, 2024Inventor: Yong Xia
-
Patent number: 11866740Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, recombinant polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides recombinant polymerases that yield lower systematic error rates and/or improved accuracy, when used in sequencing by synthesis reactions as compared to a control polymerase. In one aspect, the disclosure relates to recombinant polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In another aspect, the recombinant polymerases are useful for the amplification of nucleic acid templates during PCR, emPCR, isothermal amplification, recombinase polymerase amplification, rolling circle amplification, strand displacement amplification and proximity ligation amplification.Type: GrantFiled: May 7, 2021Date of Patent: January 9, 2024Assignee: Life Technologies CorporationInventors: Daniel Mazur, Peter B. Vander Horn, Eileen Tozer, Sihong Chen, Guobin Luo, Joshua Shirley, Kevin Heinemann
-
Patent number: 11859247Abstract: The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing.Type: GrantFiled: June 23, 2021Date of Patent: January 2, 2024Assignee: Oxford Nanopore Technologies PLCInventors: Lakmal Jayasinghe, John Hagan Pryce Bayley, Stephen Cheley, Brian McKeown, James White, James Clarke
-
Patent number: 11834685Abstract: Covalently-linked DNA polymerases are provided.Type: GrantFiled: April 8, 2021Date of Patent: December 5, 2023Assignee: BIO-RAD LABORATORIES, INC.Inventor: Xiao-Song Gong
-
Patent number: 11827915Abstract: Enzymes and methods are described herein for manufacturing terpenes, including terpenes.Type: GrantFiled: August 2, 2019Date of Patent: November 28, 2023Assignee: Board of Trustees of Michigan State UniversityInventors: Björn Hamberger, Sean Johnson, Wajid Waheed Bhat
-
Patent number: 11814655Abstract: Provided are mutant polymerases having DNA polymerase activity and reverse transcriptase activity or strand displacement activity, along with target nucleic acid amplification methods employing such mutant polymerases.Type: GrantFiled: May 28, 2021Date of Patent: November 14, 2023Assignee: DNA POLYMERASE TECHNOLOGY, INC.Inventors: Wayne M. Barnes, Milko B. Kermekchiev, Zhian Zhang
-
Patent number: 11807887Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.Type: GrantFiled: December 17, 2021Date of Patent: November 7, 2023Assignee: Nuclera, Ltd.Inventors: Michael C. Chen, Radu A. Lazar, Jiahao Huang, Gordon R. McInroy
-
Patent number: 11807667Abstract: The present invention provides novel engineered polypeptides that support both reverse transcription and DNA amplification in manganese-independent reactions. The present invention also provides methods for amplifying template nucleic acids using such polypeptides. This invention addresses deficiencies in the current state of the art in nucleic acid amplification-based detection of template nucleic acids, especially RNA targets, including deficiencies in detection sensitivity, specificity, enzyme stability, inhibitor tolerance and time to result compared with manganese-dependent thermostable reverse transcriptases and two-enzyme solutions.Type: GrantFiled: April 30, 2019Date of Patent: November 7, 2023Assignee: QIAGEN BEVERLY, LLC.Inventors: Thomas William Schoenfeld, Ryan Charles Heller, Katarzyna Crissy, Suhman Chung